Effective treatments for atopic dermatitis (AD) are highly sought after. Here the authors develop ucenprubart (LY3454738) for treating AD and find, in a randomized, multiple arms, multicenter, placebo controlled, and dose-escalating phase 1 trial (NCT03750643) trial, ucenprubart to be safe and showing preliminary efficacy when compared with placebo at 12 weeks post treatment.
- Anja Koester
- Derrick R. Witcher
- Ajay Nirula
